IV PPI’s for bleeding ulcers

By  |  May 4, 2009 | 

In this multi-center RCT, over 700 patients with EGD-proven bleeding peptic ulcers were randomized (after endoscopy) to 72 hours of IV PPI (80mg bolus, then 8mg/hr) or placebo. Those in the PPI group had less recurrent bleeding at 72 hours (6% vs 10%) and less endoscopic re-treatment (6% vs 12%), surgery (3% vs 5%), and death (1% vs 2%). Of note, this only applies to post-endoscopy bleeding peptic ulcers, and does not address either oral PPI therapy, or pre-endoscopy PPI therapy (abstract).

Leave A Comment

About the Author: Danielle Scheurer

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.


Related Posts

By  | June 29, 2013 |  0
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
By  | June 22, 2013 |  0
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
By  | May 25, 2013 |  0
This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]